Dr Tony Gill is a public health physician who is a Principal Medical Adviser in the Therapeutic Goods Administration (TGA) and heads up the Clinical Evaluation Section 6 (Advanced and Biological Therapies) in the Prescription Medicines Authorisation Branch, Medicines Regulation Division. In this role, he heads up a section involved in the clinical evaluation and market authorisation decision making for gene therapies and cell therapies as well as being involved in developing policy on emerging advanced therapies.
He commenced work at the TGA in February 2010 and has filled various roles including acting Chief Medical Adviser of the TGA and Senior Medical Adviser roles until before moving to his current position in February 2022. In the TGA, he has been involved in the regulation of unapproved therapeutic goods, the clinical evaluation of medicines, biologicals and medical devices, and the scheduling of medicines. Dr Gill was also the lead for the introduction of TGA’s medicine shortages section and its medicinal cannabis section.
Session objectives:
